- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02759666
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors
A Multicenter, Open-Label, Phase 1 Trial of SHR3162 Given Orally to Subjects With Advanced Solid Tumors
Study Overview
Detailed Description
Poly adenosine diphosphate (ADP)-ribose polymerase (PARP) is a family of proteins that plays important roles in multiple cellular processes, including single-strand DNA breaks, which if left unrepaired, leads to double-strand breaks (DSB) during DNA replication. The DSB can be repaired either through error-free homologous recombination (HR) or error-prone non-homology end joining. In HR deficient cancer cells with mutations on HR genes such as BRCA1, BRCA2 or partner and localizer of BRCA2 (PALB2), DSB cannot be efficiently and correctly repaired, resulting in cell death. Viable cells, on the other hand, have normal HR and do not replicate as often as cancer cells; thus they can survive PARP inhibition. PARP inhibitors are being actively developed worldwide as promising anti-tumor therapeutics. The current trial will be conducted in participants with advanced solid tumors for whom satisfactory treatments are not yet available.
In the dose-escalation phase, patients will be enrolled sequentially into the 8 dose levels of SHR3162 designated in this study(3-6 patients per cohort). One to two sentinel participants in Cohort 1 who will be treated and closely monitored for 24 hours. If no adverse effects are noted during the 24-hour period, dosing of further participants in the cohort may continue.
In the dose expansion part of the study, up to 12 additional participants will be enrolled at the MTD.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Melbourne, Australia
- Linear
-
-
New South Wales
-
Albury, New South Wales, Australia, 2640
- Border Medical Oncology
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and/or females over age 18.
- Ability to understand the purposes and risks of the trial and his/her signed informed consent form approved by Human Research Ethics Committee (HREC) of the trial site was obtained before the entering the trial.
- Histologically or cytologically confirmed advanced or metastatic solid tumor for which no established standard therapy is available.
- At least one measurable lesion by CT or MRI according to RECIST Version 1.1, which is not in irradiated area (only for expansion phase).
- Recovered from toxicities of prior anti-cancer treatment to Grade 1 or less (in case of alopecia, Grade 2 is acceptable).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy of at least 3 months.
Acceptable liver function defined below:
- Total bilirubin ≤1.5 times upper limit of normal (ULN);
- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 times ULN; however, ≤5 times ULN in a participant who has liver metastases or is treated with biliary drainage
Acceptable renal function defined below:
- Serum creatinine ≤1.5 times ULN or calculated creatinine clearance (by the Cockcroft-Gault formula) ≥60 mL/minutes
Acceptable coagulation status defined below:
- Prothrombin time <1.3 times ULN
- Partial thrombin time <1.3 times ULN
Acceptable hematologic status (without hematologic supports including hematopoietic factor, blood transfusion) defined below:
- Absolute neutrophil count (ANC) ≥1500/μL
- Platelet count ≥100000/μL
- Hemoglobin ≥9.0 g/dL
- No clinically significant abnormalities in urinalysis.
- Female participants of child bearing potential agree not to be pregnant or lactating during the study and for three months following the last dose of study drug. Both men and women of reproductive potential must agree to use a highly effective method of birth control during the study and for three months following the last dose of study drug. A highly effective method of contraception is defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly.
Exclusion Criteria:
- Hematologic malignancies.
- Cardiac disease with New York Heart Association (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular disease.
- Previously treated malignancies other than the current disease, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years at the trial entry.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
- Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery.
- Percutaneous coronary intervention conducted within 6 months prior to the trial entry for cardiac infarction or angina pectoris.
- Seizure disorders requiring anticonvulsant therapy.
- Taking a medication that prolongs QT interval and has a risk of Torsade de Pointes, or a history of long QT syndrome.
- Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product.
- Anti-cancer treatment with radiation therapy, surgery, chemotherapy, targeted therapies (erlotinib, lapatinib, etc.), hormone therapy, or immunotherapy within 4 weeks (6 weeks for nitrosoureas or Mitomycin C) prior to trial entry, and ever use PARP inhibitor.
- Participation in an investigational drug or device trial within 4 weeks prior to the trial entry.
- Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
- Recent venous thrombosis (including deep vein thrombosis or pulmonary embolism within 1 year of study).
- History of upper gastrointestinal hemorrhage, peptic ulcer disease, or bleeding diathesis.
- Subject is pregnant (positive serum beta human chorionic gonadotropin [β-HCG] test at screening) or is currently breast-feeding, their partner anticipates becoming pregnant/impregnating during the trial or within 6 months after receiving the last dose of trial treatment.
- History of organ allograft, autologous stem cell transplantation, or allogeneic -
- Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial.
- Unwillingness or inability to comply with the trial protocol for any reason.
- Legal incapacity or limited legal capacity.
- Known drug abuse or alcohol abuse.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SHR3162
3 to 6 participants (traditional "3+3" design) will be enrolled in 6 dose levels.
SHR3162 was administered once daily in dose levels 1 and 2 and will be administered twice daily in dose levels 3 to 6.
|
SHR3162 capsule(s) is administered orally QD.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD)
Time Frame: 4 weeks
|
MTD will be defined as the maximum dose level at which no more than one 1 of 3 participants experience a dose-limiting toxicity (DLT) within the first 4 weeks of multiple dosing
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clearance (CL)
Time Frame: 4 weeks
|
4 weeks
|
Number of participants with treatment-emergent adverse events
Time Frame: 24 months
|
24 months
|
Peak plasma concentration (Cmax)
Time Frame: 4 weeks
|
4 weeks
|
Area under the plasma concentration versus time curve (AUC)
Time Frame: 4 weeks
|
4 weeks
|
T1/2 (half-life)
Time Frame: 4 weeks
|
4 weeks
|
Volume of distribution at steady state (Vss)
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR3162-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRefractory Solid Tumors | Relapsed Solid TumorsChina
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
Clinical Trials on SHR3162
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHealthy Adult Male and Female Volunteers
-
Atridia Pty Ltd.Completed
-
Atridia Pty Ltd.CompletedProstate Cancer | NeoplasmAustralia
-
Jiangsu HengRui Medicine Co., Ltd.UnknownProstate Cancer | Castration-resistant Prostate CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownAdvanced Pancreatic CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Tianjin Medical University Second HospitalUnknownSmall Cell Lung Cancer Extensive StageChina
-
Jiangsu HengRui Medicine Co., Ltd.Peking University Cancer Hospital & InstituteCompletedOvarian Cancer | Triple Negative Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Terminated